05 December 2023
05 December 2023
A statement issued by leading industry bodies emphasises climate change as an urgent health challenge at COP28, as the president defends fossil fuel use.
The safety database in the NDA comprises more than 1,000 patients with exposures of up to 12 weeks.
Abbisko is eligible to receive a down payment of $70m from Merck KGaA (Merck).
The agreement allows Guardant Health to leverage Cancer Research UK’s network to validate its technologies.
Palvella will receive $5m as an upfront payment, with Ligand getting 8%-9.8% in tiered royalties on worldwide sales of Qtorin rapamycin.
The latest investment takes the funds raised by the company to a total of $222m.
Everest’s clinical trial in China will contribute to Kezar’s global PALIZADE study of zetomipzomib for lupus nephritis
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
The success of CAR-Ts in MM has fueled R&D investment into this class of therapy, with more CAR-Ts in development than all other cell and gene therapy classes combined. The approval of the autologous CAR-T cell therapies Abecma and Carvykti sees the CAR-T pipeline mostly constituted of autologous drugs. However, there are also multiple allogeneic CAR-Ts in the pipeline.
Only a handful of approved therapeutic drugs are currently available for the treatment of ARF, all belonging to the solute carrier family 12 member 1 inhibitor. The clinical trial space in ARF consists of almost an equal mix of commercial as well as academic sponsors, with Iran and the US emerging as the key countries for conducting Phase III trials.
Give your business an edge with our leading industry insights.
